Christopher Bischoff Acquires 4,000 Shares of Livongo Health (NASDAQ:LVGO) Stock

Livongo Health (NASDAQ:LVGO) Director Christopher Bischoff acquired 4,000 shares of the stock in a transaction dated Monday, November 18th. The stock was bought at an average cost of $25.48 per share, with a total value of $101,920.00. Following the completion of the purchase, the director now directly owns 4,000 shares in the company, valued at $101,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of LVGO stock traded down $0.01 on Monday, reaching $25.55. 520,700 shares of the company’s stock were exchanged, compared to its average volume of 1,100,767. Livongo Health has a 52 week low of $15.12 and a 52 week high of $45.68. The business has a fifty day moving average of $21.12.

Livongo Health (NASDAQ:LVGO) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.23. Livongo Health had a negative return on equity of 119.92% and a negative net margin of 43.59%. The firm had revenue of $46.70 million during the quarter, compared to analyst estimates of $42.77 million. During the same period last year, the company earned ($0.55) EPS. Livongo Health’s quarterly revenue was up 148.7% compared to the same quarter last year. On average, equities research analysts anticipate that Livongo Health will post -1.38 earnings per share for the current fiscal year.

LVGO has been the subject of several analyst reports. JPMorgan Chase & Co. initiated coverage on Livongo Health in a research note on Monday, August 19th. They issued an “overweight” rating and a $43.00 price objective for the company. Zacks Investment Research raised Livongo Health from a “sell” rating to a “hold” rating in a research note on Saturday, November 2nd. Canaccord Genuity initiated coverage on Livongo Health in a research note on Monday, August 19th. They issued a “buy” rating and a $46.00 price objective for the company. Morgan Stanley raised Livongo Health from an “equal weight” rating to an “overweight” rating and set a $42.00 price objective for the company in a research note on Wednesday, August 28th. Finally, Needham & Company LLC initiated coverage on Livongo Health in a research note on Monday, August 19th. They issued a “buy” rating and a $42.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $44.30.

Several hedge funds have recently modified their holdings of the stock. Emerald Advisers LLC bought a new stake in shares of Livongo Health during the 3rd quarter worth approximately $1,342,000. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Livongo Health during the 3rd quarter worth approximately $1,292,000. Pembroke Management LTD bought a new stake in shares of Livongo Health during the 3rd quarter worth approximately $1,128,000. Dean Capital Investments Management LLC bought a new stake in shares of Livongo Health during the 3rd quarter worth approximately $275,000. Finally, Rhumbline Advisers bought a new stake in shares of Livongo Health during the 3rd quarter worth approximately $238,000. 5.34% of the stock is owned by hedge funds and other institutional investors.

Livongo Health Company Profile

Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.

See Also: What are the risks of holding treasury bonds?

Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.